Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 17555985)


Dietary histone deacetylase inhibitors: from cells to mice to man.

Dashwood RH, Ho E.

Semin Cancer Biol. 2007 Oct;17(5):363-9. Epub 2007 May 5. Review.


Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.

Nian H, Delage B, Ho E, Dashwood RH.

Environ Mol Mutagen. 2009 Apr;50(3):213-21. doi: 10.1002/em.20454. Review.


Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.

Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E.

Exp Biol Med (Maywood). 2007 Feb;232(2):227-34.


Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice.

Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH.

FASEB J. 2006 Mar;20(3):506-8. Epub 2006 Jan 11.


A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.

Myzak MC, Karplus PA, Chung FL, Dashwood RH.

Cancer Res. 2004 Aug 15;64(16):5767-74.


Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.

Clarke JD, Hsu A, Yu Z, Dashwood RH, Ho E.

Mol Nutr Food Res. 2011 Jul;55(7):999-1009. doi: 10.1002/mnfr.201000547. Epub 2011 Mar 4.


Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.

Rajendran P, Delage B, Dashwood WM, Yu TW, Wuth B, Williams DE, Ho E, Dashwood RH.

Mol Cancer. 2011 May 30;10:68. doi: 10.1186/1476-4598-10-68.


Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention.

Ho E, Clarke JD, Dashwood RH.

J Nutr. 2009 Dec;139(12):2393-6. doi: 10.3945/jn.109.113332. Epub 2009 Oct 7.


Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.

Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E.

Carcinogenesis. 2006 Apr;27(4):811-9. Epub 2005 Nov 9.


Epigenetic impact of dietary isothiocyanates in cancer chemoprevention.

Gerhauser C.

Curr Opin Clin Nutr Metab Care. 2013 Jul;16(4):405-10. doi: 10.1097/MCO.0b013e328362014e. Review.


Multi-targeted prevention of cancer by sulforaphane.

Clarke JD, Dashwood RH, Ho E.

Cancer Lett. 2008 Oct 8;269(2):291-304. doi: 10.1016/j.canlet.2008.04.018. Epub 2008 May 27. Review.


Sulforaphane causes a major epigenetic repression of myostatin in porcine satellite cells.

Fan H, Zhang R, Tesfaye D, Tholen E, Looft C, Hölker M, Schellander K, Cinar MU.

Epigenetics. 2012 Dec 1;7(12):1379-90. doi: 10.4161/epi.22609. Epub 2012 Oct 23.


Dietary agents as histone deacetylase inhibitors.

Myzak MC, Ho E, Dashwood RH.

Mol Carcinog. 2006 Jun;45(6):443-6. Review.


Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter.

Nian H, Delage B, Pinto JT, Dashwood RH.

Carcinogenesis. 2008 Sep;29(9):1816-24. doi: 10.1093/carcin/bgn165. Epub 2008 Jul 14.


The dietary histone deacetylase inhibitor sulforaphane induces human beta-defensin-2 in intestinal epithelial cells.

Schwab M, Reynders V, Loitsch S, Steinhilber D, Schröder O, Stein J.

Immunology. 2008 Oct;125(2):241-51. doi: 10.1111/j.1365-2567.2008.02834.x. Epub 2008 Mar 27.


Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines.

Meeran SM, Patel SN, Tollefsbol TO.

PLoS One. 2010 Jul 6;5(7):e11457. doi: 10.1371/journal.pone.0011457.


Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?

Dashwood RH, Myzak MC, Ho E.

Carcinogenesis. 2006 Feb;27(2):344-9. Epub 2005 Nov 2. Review.


HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.

Rajendran P, Kidane AI, Yu TW, Dashwood WM, Bisson WH, Löhr CV, Ho E, Williams DE, Dashwood RH.

Epigenetics. 2013 Jun;8(6):612-23. doi: 10.4161/epi.24710. Epub 2013 Apr 26.


Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.

Santini V, Gozzini A, Ferrari G.

Curr Drug Metab. 2007 May;8(4):383-93. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk